BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM • US1101221083
51.13 EUR
0 (0%)
Last: Feb 13, 2026, 07:00 PM
Overall BRM gets a fundamental rating of 5 out of 10. We evaluated BRM against 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM is valued quite cheap, but it does not seem to be growing. BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- In the past year BRM was profitable.
- In the past year BRM had a positive cash flow from operations.
- Of the past 5 years BRM 4 years were profitable.
- Of the past 5 years BRM 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.23%, BRM is in line with its industry, outperforming 50.91% of the companies in the same industry.
- BRM has a Return On Equity of 32.55%. This is in the better half of the industry: BRM outperforms 78.18% of its industry peers.
- BRM's Return On Invested Capital of 17.64% is fine compared to the rest of the industry. BRM outperforms 70.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 17.64% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Profit Margin value of 12.57%, BRM perfoms like the industry average, outperforming 45.45% of the companies in the same industry.
- BRM's Profit Margin has improved in the last couple of years.
- BRM has a Operating Margin of 33.51%. This is in the better half of the industry: BRM outperforms 80.00% of its industry peers.
- BRM's Operating Margin has improved in the last couple of years.
- BRM's Gross Margin of 73.15% is in line compared to the rest of the industry. BRM outperforms 56.36% of its industry peers.
- In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
- BRM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- BRM has an Altman-Z score of 2.33. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
- BRM has a Altman-Z score of 2.33. This is comparable to the rest of the industry: BRM outperforms 45.45% of its industry peers.
- The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of BRM (3.20) is better than 65.45% of its industry peers.
- BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
- BRM has a worse Debt to Equity ratio (2.41) than 83.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.33 |
ROIC/WACC2.09
WACC8.43%
2.3 Liquidity
- A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
- BRM's Current ratio of 1.27 is on the low side compared to the rest of the industry. BRM is outperformed by 61.82% of its industry peers.
- BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of BRM (1.17) is better than 67.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
- The Earnings Per Share has been decreasing by -0.92% on average over the past years.
- Looking at the last year, BRM shows a decrease in Revenue. The Revenue has decreased by -0.22% in the last year.
- BRM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- Based on estimates for the next years, BRM will show a decrease in Earnings Per Share. The EPS will decrease by -4.54% on average per year.
- BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.61% yearly.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 9.87, which indicates a very decent valuation of BRM.
- Based on the Price/Earnings ratio, BRM is valued cheaper than 89.09% of the companies in the same industry.
- BRM is valuated cheaply when we compare the Price/Earnings ratio to 26.68, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 9.97 indicates a reasonable valuation of BRM.
- 83.64% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.87 | ||
| Fwd PE | 9.97 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaper than 90.91% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 98.18% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.07 | ||
| EV/EBITDA | 7.37 |
4.3 Compensation for Growth
- A cheap valuation may be justified as BRM's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
5. Dividend
5.1 Amount
- BRM has a Yearly Dividend Yield of 4.21%, which is a nice return.
- Compared to an average industry Dividend Yield of 1.89, BRM pays a better dividend. On top of this BRM pays more dividend than 87.27% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.84, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
5.2 History
- The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- 82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
- BRM's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
FRA:BRM (2/13/2026, 7:00:00 PM)
51.13
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap104.09B
Revenue(TTM)48.19B
Net Income(TTM)6.04B
Analysts70.59
Price Target48.84 (-4.48%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.21% |
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.55%
PT rev (3m)7.06%
EPS NQ rev (1m)-29.59%
EPS NQ rev (3m)-32.32%
EPS NY rev (1m)0.39%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.87 | ||
| Fwd PE | 9.97 | ||
| P/S | 2.57 | ||
| P/FCF | 8.07 | ||
| P/OCF | 7.43 | ||
| P/B | 6.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.37 |
EPS(TTM)5.18
EY10.13%
EPS(NY)5.13
Fwd EY10.03%
FCF(TTM)6.34
FCFY12.39%
OCF(TTM)6.88
OCFY13.46%
SpS19.89
BVpS7.68
TBVpS-9.8
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 17.64% | ||
| ROICexc | 23.19% | ||
| ROICexgc | 118.19% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.33 |
F-Score6
WACC8.43%
ROIC/WACC2.09
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.61%
EBIT growth 1Y44.7%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y10.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.78%
OCF growth 3YN/A
OCF growth 5YN/A
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to BRM.DE.
What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 4 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -1.05% in the next year.
Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?
The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 82.81%.